Plain-English translation of NCT06148298 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Pancreatic cancer is very hard to detect early, which is why survival rates are low. This research is testing a new type of blood test that looks for specific signs of pancreatic cancer in your bloodstream. The goal is to find a quick, affordable way to catch pancreatic cancer earlier, when treatment is more likely to work.
Currently, pancreatic cancer is often found too late because the only reliable screening tools (like MRI scans) are expensive and not accessible to many people. This study exists because researchers believe a simple blood test could provide the same early-detection benefits at a fraction of the cost.
You likely qualify if…
You likely don't qualify if…
As a participant, you would donate a blood sample that researchers will analyze using a special test to detect cancer-related signals in your blood. The study is small (enrolling 24 people total) and is currently recruiting participants. Based on the design, you can expect a straightforward visit where blood is drawn — similar to a standard lab test.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Enrollment target
~24 participants
Started
May 2023
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Amoy Fraser, PhD, CCRP, PMP
University of Central Florida
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.